*For medical professionals for reference
Invited experts and scholars in this issue of "Antipolutarian Coffee Talk" to discuss AMI patients with the latest research of 2024 ESCNew progress in high -efficiency antarr thrombosis strategies.
Acute myocardial infarction (AMI) as Speed and critical illnesses in the disease, its mortality rate is still high.It is also a major challenge that needs to be solved urgently.With the advancement of medical technology and the deepening of research, anti -platelet treatment has become an indispensable core link in AMI treatment.Dual -combined anti -platelet therapy (DAPT) can effectively inhibit platelet activity and reduce thrombosis events through joint application of P2Y12 receptor inhibitors and aspirin.However, researchers have found that DAPTs treatment and drug selection need to be more individualized.On the one hand, continuous anti -platelet therapy will increase the risk of bleeding, so it is necessary to find a balance point between the risk of ischemia and bleeding.On the other hand, there are differences in clinical characteristics and prognosis of different patients. Therefore, antiphantal treatments need to be formulated according to the specific conditions of the patient.At the annual meeting of the European Cardiac Society (ESC) this year, a series of latest AMI research results were announced. For example, among elderly AMI patients, the first choice of Grenaro treatment in the acute period of myocardial infarction can reduce the patients 5 -year mortality and bring long -term long -termSurvival benefits [1].The results of these studies opened a new perspective for clinical AMI therapy and perioprocol arterial intervention (PCI) perioperative management.
Based on this, "Medical Hearts" Cardiovascular Medicine Clinical Diagnosis and Treatment Improving Project "Antipolutarian Coffee Talk 70" will be in 2024On November 12th (Tuesday) 19:00 to 20:30, it was launched. Professor Mao Wei, Zhejiang Hospital, Professor Yang Wenyi, Shanghai First Peoples Hospital, Professor Shan Peiren, First Affiliated Hospital of Wenzhou Medical UniversityProfessor Qiu Fuyu of Shao Yifu Hospital of Zhejiang University Medical College and Professor Miafei, Taizhou Hospital in Zhejiang Province Interpret the latest hotspot research in 2024 ESC, and explore new progress in individual anti -thrombus management during AMI patients and PCI perioperative period.Helps further standardize clinical diagnosis and treatment.
See the poster in the live broadcast schedule. Please look forward to it!
References:
[1] .o weizman, Et Al. One-and Five-Year Mortality According to First Use of ticagrelor or Clopidogrel at the Acute Stage of Myocardial Infartion in Elderly Patients: Mi 2015 registry. Presented at: ESC CONGRESS 2024.
More exciting content of the cardiovascular vascular
Come " Doctor Station Network Page version "Look at it
Wonderful information is waiting for youCome
*Only for push for the medical industry, only for medical and health professionals, and must not be reposted or shared non -medical professionals.
